-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Q3 2023 EPS Estimates for Reunion Neuroscience Inc. (NASDAQ:REUN) Raised by Analyst
Q3 2023 EPS Estimates for Reunion Neuroscience Inc. (NASDAQ:REUN) Raised by Analyst
Reunion Neuroscience Inc. (NASDAQ:REUN – Get Rating) – Stock analysts at HC Wainwright raised their Q3 2023 earnings estimates for shares of Reunion Neuroscience in a research note issued to investors on Thursday, January 19th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.30) per share for the quarter, up from their prior forecast of ($0.31). The consensus estimate for Reunion Neuroscience's current full-year earnings is ($1.26) per share. HC Wainwright also issued estimates for Reunion Neuroscience's FY2023 earnings at ($1.19) EPS, FY2025 earnings at ($0.31) EPS, FY2026 earnings at ($0.36) EPS and FY2027 earnings at ($0.40) EPS.
Get Reunion Neuroscience alerts:A number of other equities analysts have also commented on the stock. Stifel Nicolaus decreased their price target on shares of Reunion Neuroscience from C$15.00 to C$5.50 in a report on Tuesday, November 15th. Bloom Burton reaffirmed a "buy" rating on shares of Reunion Neuroscience in a report on Monday, November 28th. Finally, EF Hutton Acquisition Co. I began coverage on shares of Reunion Neuroscience in a report on Friday, December 16th. They set a "buy" rating and a $11.00 target price on the stock.
Reunion Neuroscience Stock Performance
Shares of NASDAQ:REUN opened at $1.33 on Monday. The business has a fifty day moving average of $1.24. Reunion Neuroscience has a one year low of $0.76 and a one year high of $10.47.Reunion Neuroscience (NASDAQ:REUN – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.50).
Institutional Investors Weigh In On Reunion Neuroscience
Several institutional investors have recently added to or reduced their stakes in the company. Cidel Asset Management Inc. purchased a new stake in Reunion Neuroscience during the 3rd quarter valued at $29,000. Jane Street Group LLC purchased a new stake in Reunion Neuroscience during the 3rd quarter valued at $51,000. Finally, One Plus One Wealth Management LLC purchased a new stake in Reunion Neuroscience during the 3rd quarter valued at $109,000. Hedge funds and other institutional investors own 12.88% of the company's stock.
Reunion Neuroscience Company Profile
(Get Rating)
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.
Read More
- Get a free copy of the StockNews.com research report on Reunion Neuroscience (REUN)
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
Reunion Neuroscience Inc. (NASDAQ:REUN – Get Rating) – Stock analysts at HC Wainwright raised their Q3 2023 earnings estimates for shares of Reunion Neuroscience in a research note issued to investors on Thursday, January 19th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.30) per share for the quarter, up from their prior forecast of ($0.31). The consensus estimate for Reunion Neuroscience's current full-year earnings is ($1.26) per share. HC Wainwright also issued estimates for Reunion Neuroscience's FY2023 earnings at ($1.19) EPS, FY2025 earnings at ($0.31) EPS, FY2026 earnings at ($0.36) EPS and FY2027 earnings at ($0.40) EPS.
留尼汪神經科學公司(NASDAQ:REUN — 獲得評級)— HC 溫賴特的股票分析師在 1 月 19 日(星期四)向投資者發布的研究報告中提出了其 3 年第 3 季度的收益估計,對留尼汪神經科學的股票。韋賴特分析師特魯基奧現在預計,該公司將在本季度的每股收入(0.30 美元),高於其先前的預測(0.31 美元)。團圓神經科學目前全年收益的共識估計為每股(1.26 美元)。溫賴特還發布了留尼汪神經科學的 FY2023 盈利為每股盈利(1.19 美元)、每股盈利(0.31 美元)的 FY2025 盈利、FY2026 盈利(每股收益 0.36 美元)和 FY2027 盈利(0.40 美元)的估計值。
A number of other equities analysts have also commented on the stock. Stifel Nicolaus decreased their price target on shares of Reunion Neuroscience from C$15.00 to C$5.50 in a report on Tuesday, November 15th. Bloom Burton reaffirmed a "buy" rating on shares of Reunion Neuroscience in a report on Monday, November 28th. Finally, EF Hutton Acquisition Co. I began coverage on shares of Reunion Neuroscience in a report on Friday, December 16th. They set a "buy" rating and a $11.00 target price on the stock.
一些其他股票分析師也對股票發表了評論。在 11 月 15 日(星期二)的一份報告中,斯蒂菲爾·尼古拉斯(Stifel Nicolaus)將團圓神經科學股票的價格目標從 15.00 加元降至 5.50 加元。布魯姆·伯頓在週一的報告中重申了團圓神經科學股份的「買入」評級, 11 月 28 日.最後, EF 赫頓收購有限公司.我開始報導團圓神經科學的股份在星期五的報告, 12 月 16 日.他們在股票上設定了「買入」評級和 11.00 美元的目標價格。
Reunion Neuroscience Stock Performance
留尼旺神經科學股票表現
Reunion Neuroscience (NASDAQ:REUN – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.50).
團圓神經科學 (NASDAQ: REUN — 獲取評級) 上次發布了其季度收益業績週一, 11 月 14 日.該公司報告了本季度每股收益(0.92 美元),缺少分析師的共識估計(0.42 美元)(0.50 美元)。
Institutional Investors Weigh In On Reunion Neuroscience
機構投資者權衡團圓神經科學
Several institutional investors have recently added to or reduced their stakes in the company. Cidel Asset Management Inc. purchased a new stake in Reunion Neuroscience during the 3rd quarter valued at $29,000. Jane Street Group LLC purchased a new stake in Reunion Neuroscience during the 3rd quarter valued at $51,000. Finally, One Plus One Wealth Management LLC purchased a new stake in Reunion Neuroscience during the 3rd quarter valued at $109,000. Hedge funds and other institutional investors own 12.88% of the company's stock.
一些機構投資者最近增加或減少了他們在公司的股份。Cidel 資產管理公司在第三季度購買了團圓神經科學的新股份,價值為 29,000 美元。簡街集團有限責任公司在第三季度購買了留尼旺神經科學的新股份,價值為 $51,000。最後,一加壹財富管理有限責任公司在第三季度購買了留尼汪神經科學的新股份,價值為 109,000 美元。對沖基金和其他機構投資者擁有公司股票的 12.88%。
Reunion Neuroscience Company Profile
留尼旺神經科學公司簡介
(Get Rating)
(取得評分)
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.
實地考察健康有限公司從事北美迷幻輔助療法的開發和交付。該公司經營提供迷幻療法的實地考察健康中心;提供 Field Trip 數字應用程序;經營 Field Trip Discovery,開發下一代迷幻分子的藥物開發部門;並為抑鬱症,焦慮,成癮和其他疾病提供氯胺酮輔助療法。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Reunion Neuroscience (REUN)
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- 獲取有關團圓神經科學研究報告的免費副本
- 維珍銀河股票是否準備升降?
- 雪佛龍很可能在盈利前增加股息
- 市場節拍週的回顧 — 1/16 — 1/20
- 老自治領是否顯示卡車正在擊中剎車?
- 諾德斯特龍將對減價的恐懼放入零售業
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
接收團圓神經科學日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關團圓神經科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧